The role of binding kinetics in GPCR drug discovery

Current Topics in Medicinal Chemistry

Volumn 15, Issue 24, 2015, Pages 2504-2522

  Swinney, David C ^a   Haubrich, Brad A ^a   Van Liefde, Isabelle ^b   Vauquelin, Georges ^b  

^a Institute for Rare and Neglected Diseases Drug Discovery   (United States)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Association rate; Binding kinetics; Dissociation rate; GPCR; PK PD; Rebinding; Residence time

Indexed keywords

8 CHLORO 2, 3, 4, 5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENOSINE A2A RECEPTOR; AMBRISENTAN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BOSENTAN; CANDESARTAN HEXETIL; CHEMOKINE RECEPTOR CCR5; CLOZAPINE; DIPRENORPHINE; DOPAMINE 2 RECEPTOR; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR; LOSARTAN; MACITENTAN; MUSCARINIC M3 RECEPTOR; OLMESARTAN; OLODATEROL; PARATHYROID HORMONE; QUETIAPINE; SARTAN DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CALCIUM CELL LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; PULMONARY HYPERTENSION; ANIMAL; BINDING SITE; DRUG EFFECTS; KINETICS; METABOLISM;

ANIMALS; BINDING SITES; DRUG DISCOVERY; HUMANS; KINETICS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84942122795     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150701113054     Document Type: Article

References (165)

1. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov., 2006, 5, 730-739.
2. Swinney, D. C. Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discov., 2004, 3, 801-808.
3. Swinney, D. C. Application of binding kinetics to drug discovery: translation to binding mechanisms to clinically differentiated medicines. Pharm. Med., 2008, 22, 23-34.
4. Paton, W. D. M. A theory of drug action based on the rate of drugreceptor combination. Proc. R. Soc. Lond. B. Biol. Sci., 1961, 154, 21-69.
5. Paton, W. D. M. The principles of drug action. Proc. R. Soc. Med., 1960, 53, 815-820.
6. Swinney, D. C. Can binding kinetics translate to a clinically differentiated drug? From theory to practice. Lett. Drug Des. Disc., 2006, 3, 569-574.
7. Baker, D.; Agard, D. A. Kinetics versus thermodynamics in protein folding. Biochemistry, 1994, 33, 7505-7509.
8. Ehrlich, P. Chemotherapeutics: scientific principles, methods, and results. Lancet, 1915, 182, 445-451.
9. Lanzavecchia, A.; Iezzi, G.; Viola, A. From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell, 1999, 96, 1-4.
10. Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 1995, 80, 179-185.
11. Hopfield, J. J. The energy relay: a proofreading scheme based on dynamic cooperativity and lacking all characteristic symptoms of kinetic proofreading in DNA replication and protein synthesis. Proc. Natl. Acad. Sci. U. S. A., 1980, 77, 5248-5252.
12. Coe, J. W.; Brooks, P. R.; Vetelino, M. G.; Wirtz, M. C.; Arnold, E. P.; Huang, J.; Sands, S. B.; Davis, T. I.; Lebel, L. A.; Fox, C. B.; Shrikhande, A.; Heym, J. H.; Schaeffer, E.; Rollema, H.; Lu, Y.; Mansbach, R. S.; Chambers, L. K.; Rovetti, C. C.; Schulz, D. W.; Tingley, F. D., 3rd; O'Neill, B. T. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem., 2005, 48, 3474-3477.
13. Lipton, S. A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov., 2006, 5, 160-170.
14. Kapur, S.; Seeman, P. T Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry, 2001, 158, 360-369.
15. Swinney, D. C. Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr. Top. Med. Chem., 2006, 6, 461-478.
16. Seeman, P.; Chau-Wong, M.; Tedesco, J.; Wong, K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc. Natl. Acad. Sci. U. S. A., 1975, 72, 4376-4380.
17. Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature, 1976, 261, 717-719.
18. Creese, I.; Burt, D. R.; Snyder, S. H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 1976, 192, 481-483.
19. Farde, L. The advantage of using positron emission tomography in drug research. Trends Neurosci., 1996, 19, 211-214.
20. Farde, L.; Nordstrom, A. L. PET examination of central D2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs. Psychopharmacol. Ser., 1993, 10, 94-100.
21. Raleigh, F. Use of novel antipsychotic drugs. Pharmacotherapy, 1996, 16, 160S-165S.
22. Petty, R. G. Prolactin and antipsychotic medications: mechanism of action. Schizophr. Res., 1999, 35 Suppl, S67-S73.
23. Kapur, S.; Seeman, P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci., 2000, 25, 161-166.
24. Seeman, P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry, 2002, 47, 27-38.
25. Farah, A. Atypicality of atypical antipsychotics. Prim. Care Companion J. Clin. Psychiatry, 2005, 7, 268-274.
26. Langlois, X. M., A.; Lavreysen, H.; Wouters, R.; Peeters, L.; te Riele, P.; Hendrickx, H.; Mahieu, M.; de Bruyn ,M.; Macdonald, G In: 23rd Congress of The European College Of Neuropsychopharmacology (ECNP), Amsterdam, The Netherlands, August 28 -September 1, 2010. Eur. Neuropsychopharmacol., 20 (Suppl.3), P.S502 2010; pp. 20.
27. Seeman, P. An update of fast-off dopamine D2 atypical antipsychotics. Am. J. Psychiatry, 2005, 162, 1984-1985.
28. Seeman, P.; Tallerico, T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry, 1998, 3, 123-134.
29. Kawagoe, K. T.; Garris, P. A.; Wiedemann, D. J.; Wightman, R. M. Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience, 1992, 51, 55-64.
30. Koepp, M. J.; Gunn, R. N.; Lawrence, A. D.; Cunningham, V. J.; Dagher, A.; Jones, T.; Brooks, D. J.; Bench, C. J.; Grasby, P. M. Evidence for striatal dopamine release during a video game. Nature, 1998, 393, 266-268.
31. Olson, T. P. Does clozapine work by blocking spikes and sparing bursts? Med. Hypotheses, 2005, 65, 68-78.
32. Salimpoor, V. N.; Benovoy, M.; Larcher, K.; Dagher, A.; Zatorre, R. J. Anatomically distinct dopamine release during anticipation and experience of peak emotion to music. Nat. Neurosci., 2011, 14, 257-262.
33. Schultz, W. Multiple dopamine functions at different time courses. Annu. Rev. Neurosci., 2007, 30, 259-288.
34. Dreyer, J. K.; Herrik, K. F.; Berg, R. W.; Hounsgaard, J. D. Influence of phasic and tonic dopamine release on receptor activation. J. Neurosci., 2010, 30, 14273-14283.
35. Vauquelin, G.; Bostoen, S.; Vanderheyden, P.; Seeman, P. Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn. Schmiedebergs Arch. Pharmacol., 2012, 385, 337-372.
36. Van Liefde, I.; Vauquelin, G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol. Cell. Endocrinol., 2009, 302, 237-243.
37. Michel, M. C.; Foster, C.; Brunner, H. R.; Liu, L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol. Rev., 2013, 65, 809-848.
38. Zhang, R.; Monsma, F. The importance of drug-target residence time. Curr. Opin. Drug Discov. Devel., 2009, 12, 488-496.
39. Ojima, M.; Igata, H.; Tanaka, M.; Sakamoto, H.; Kuroita, T.; Kohara, Y.; Kubo, K.; Fuse, H.; Imura, Y.; Kusumoto, K.; Nagaya, H. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J. Pharmacol. Exp. Ther., 2011, 336, 801-808.
40. Leff, P.; Martin, G. R. Can they be classified with the available antagonists? Br. J. Pharmacol., 1986, 88, 585-593.
41. Wienen, W.; Mauz, A. B.; Van Meel, J. C.; Entzeroth, M. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. Mol. Pharmacol., 1992, 41, 1081-1088.
42. Noda, M.; Shibouta, Y.; Inada, Y.; Ojima, M.; Wada, T.; Sanada, T.; Kubo, K.; Kohara, Y.; Naka, T.; Nishikawa, K. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem. Pharmacol., 1993, 46, 311-318.
43. Mizuno, M.; Sada, T.; Ikeda, M.; Fukuda, N.; Miyamoto, M.; Yanagisawa, H.; Koike, H. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol., 1995, 285, 181-188.
44. Mochizuki, S.; Sato, T.; Furuta, K.; Hase, K.; Ohkura, Y.; Fukai, C.; Kosakai, K.; Wakabayashi, S.; Tomiyama, A. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J. Cardiovasc. Pharmacol., 1995, 25, 22-29.
45. Vauquelin, G.; Van Liefde, I.; Vanderheyden, P. Models and methods for studying insurmountable antagonism. Trends Pharmacol. Sci., 2002, 23, 514-518.
46. Kenakin, T.; Jenkinson, S.; Watson, C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J. Pharmacol. Exp. Ther., 2006, 319, 710-723.
47. Christopoulos, A.; Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev., 2002, 54, 323-374.
48. Rang, H. P. The kinetics of action of acetylcholine antagonists in smooth muscle. Proc. R. Soc. Lond. B. Biol. Sci., 1966, 164, 488-510.
49. Fierens, F.; Vanderheyden, P. M.; De Backer, J. P.; Vauquelin, G. Euro. J. Pharmacol., 1999, 367, 413-22.
50. Fierens, F. L.; Vanderheyden, P. M.; De Backer, J. P.; Vauquelin, G. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells. Eur. J. Pharmacol., 1999, 372, 199-206.
51. Vanderheyden, P. M.; Verheijen, I.; Fierens, F. L.; Backer, J. P.; Vauquelin, G. Binding characteristics of [(3)H]-irbesartan to human recombinant angiotensin type 1 receptors. J. Renin Angiotensin Aldosterone Syst., 2000, 1, 159-165.
52. Verheijen, I.; Fierens, F. L.; Debacker, J. P.; Vauquelin, G.; Vanderheyden, P. M. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors. Fundam. Clin. Pharmacol., 2000, 14, 577-585.
53. Le, M. T.; Pugsley, M. K.; Vauquelin, G.; Van Liefde, I. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br. J. Pharmacol., 2007, 151, 952-962.
54. Gatfield, J.; Mueller Grandjean, C.; Sasse, T.; Clozel, M.; Nayler, O. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One, 2012, 7, e47662.
55. Quaschning, T.; d'Uscio, L. V.; Shaw, S.; Viswambharan, H.; Ruschitzka, F. T.; Luscher, T. F. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension. Nephrol. Dial. Transplant., 2001, 16, 1176-1182.
56. Frelin, C.; Guedin, D. Why are circulating concentrations of endothelin-1 so low? Cardiovasc. Res., 1994, 28, 1613-1622.
57. Mutsaers, S. E.; Foster, M. L.; Chambers, R. C.; Laurent, G. J.; McAnulty, R. J. Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am. J. Respir. Cell. Mol. Biol., 1998, 18, 611-619.
58. Emoto, N.; Raharjo, S. B.; Isaka, D.; Masuda, S.; Adiarto, S.; Jeng, A. Y.; Yokoyama, M. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension, 2005, 45, 1145-1152.
59. Iglarz, M.; Binkert, C.; Morrison, K.; Fischli, W.; Gatfield, J.; Treiber, A.; Weller, T.; Bolli, M. H.; Boss, C.; Buchmann, S.; Capeleto, B.; Hess, P.; Qiu, C.; Clozel, M. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J. Pharmacol. Exp. Ther., 2008, 327, 736-745.
60. Bolli, M. H.; Boss, C.; Binkert, C.; Buchmann, S.; Bur, D.; Hess, P.; Iglarz, M.; Meyer, S.; Rein, J.; Rey, M.; Treiber, A.; Clozel, M.; Fischli, W.; Weller, T. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J. Med. Chem., 2012, 55, 7849-7861.
61. Iglarz, M.; Bossu, A.; Wanner, D.; Bortolamiol, C.; Rey, M.; Hess, P.; Clozel, M. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci., 2014, 118, 333-339.
62. Gatfield, J.; Mueller Grandjean, C.; Bur, D.; Bolli, M. H.; Nayler, O. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis. PloS One 2014, 9, e107809.
63. Dahl, G.; Akerud, T. Pharmacokinetics and the drug-target residence time concept. Drug Discov .Today, 2013, 18, 697-707.
64. Le, M. T.; De Backer, J. P.; Hunyady, L.; Vanderheyden, P. M.; Vauquelin, G. Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells. Eur. J. Pharmacol., 2005, 513, 35-45.
65. Zhang, J. C.; Van Meel, A.; Pfaffendorf, M.; Van Zwieten, P. Different types of angiotensin II receptor antagonism induced by BIBS 222 in the rat portal vein and rabbit aorta; the influence of receptor reserve. J. Pharmacol. Exp. Ther., 1993, 269, 509-514.
66. Hall, D.; Parsons, S. Non-surmountable antagonism: a general drawback of pre-steady-state measurement? Trends Pharmacol. Sci., 2001, 22, 63-66.
67. Lew, M. J.; Ziogas, J. The two-state model of antagonist-AT1 receptor interaction: an hypothesis defended but not tested. Biochem. Pharmacol., 2004, 67, 397-399.
68. Bortolato, A.; Tehan, B. G.; Bodnarchuk, M. S.; Essex, J. W.; Mason, J. S. Water network perturbation in ligand binding: adenosine A(2A) antagonists as a case study. J. Chem. Inf. Model., 2013, 53, 1700-1713.
69. Mason, J. S.; Bortolato, A.; Weiss, D. R.; Deflorian, F.; Tehan, B.; Marshall, F. H. High end GPCR design: Crafted ligand design and druggability analysis using protein structure, lipophilic hotspotsand explicit water networks. In Silico Pharmacol., 2013, 1: 23.
70. Lovich, M. A.; Creel, C.; Hong, K.; Hwang, C. W.; Edelman, E. R. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J. Pharm. Sci., 2001, 90, 1324-1335.
71. Dokoumetzidis, A.; Karalis, V.; Iliadis, A.; Macheras, P. The heterogeneous course of drug transit through the body. Trends Pharmacol. Sci., 2004, 25, 140-146.
72. Hrabetova, S.; Nicholson, C. Contribution of dead-space microdomains to tortuosity of brain extracellular space. Neurochem. Int., 2004, 45, 467-477.
73. Dityatev, A.; Schachner, M. The extracellular matrix and synapses. Cell Tissue Res., 2006, 326, 647-654.
74. Spivak, C. E.; Oz, M.; Beglan, C. L.; Shrager, R. I. Diffusion delays and unstirred layer effects at monolayer cultures of Chinese hamster ovary cells: radioligand binding, confocal microscopy, and mathematical simulations. Cell. Biochem. Biophys., 2006, 45, 43-58.
75. Vargova, L.; Sykova, E. Extracellular space diffusion and extrasynaptic transmission. Physiol. Res., 2008, 57 Suppl 3, S89-S99.
76. Loftsson, T. Die Drug permeation through biomembranes: cyclodextrins and the unstirred water layer. Pharmazie, 2012, 67, 363-370.
77. Vauquelin, G. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin. Drug Discov., 2010, 5, 927-941.
78. Vauquelin, G.; Charlton, S. J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br. J. Pharmacol., 2010, 161, 488-508.
79. Perry, D. C.; Mullis, K. B.; Oie, S.; Sadee, W. Opiate antagonist receptor binding in vivo: evidence for a new receptor binding model. Brain Res., 1980, 199, 49-61.
80. Frost, J. J.; Wagner, H. N., Jr. Kinetics of binding to opiate receptors in vivo predicted from in vitro parameters. Brain Res., 1984, 305, 1-11.
81. Goldstein, B.; Dembo, M. Approximating the effects of diffusion on reversible reactions at the cell surface: ligand-receptor kinetics. Biophys. J., 1995, 68, 1222-1230.
82. Goldstein, B.; Posner, R. G.; Torney, D. C.; Erickson, J.; Holowka, D.; Baird, B. Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody. Biophys. J., 1989, 56, 955-966.
83. Vauquelin, G.; Van Liefde, I. Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems. Expert Opin. Drug Discov., 2012, 7, 583-595.
84. Sadee, W.; Perry, D. C.; Rosenbaum, J. S.; Herz, A. [3H]diprenorphine receptor binding in vivo and in vitro. Eur. J. Pharmacol., 1982, 81, 431-440.
85. Gifford, A. N.; Gatley, S. J.; Volkow, N. D. Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high-affinity PET and SPECT radiotracers. Synapse, 1998, 28, 167-175.
86. Griessner, M.; Broker, P.; Lehmann, A.; Ehrentreich-Forster, E.; Bier, F. F. Detection of angiotensin II type 1 receptor ligands by a cell-based assay. Anal. Bioanal. Chem., 2009, 395, 1937-1940.
87. Packeu, A.; De Backer, J. P.; Van Liefde, I.; Vanderheyden, P. M.; Vauquelin, G. Antagonist-radioligand binding to D2L-receptors in intact cells. Biochem. Pharmacol., 2008, 75, 2192-21203.
88. Szczuka, A.; Wennerberg, M.; Packeu, A.; Vauquelin, G. Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol. Br. J. Pharmacol., 2009, 158, 183-194.
89. Wennerberg, M.; Balendran, A.; Clapham, J. C.; Vauquelin, G. Unravelling the complex dissociation of [(3)H]-rimonabant from plated CB(1) cannabinoid receptor-expressing cells. Fundam. Clin. Pharmacol., 2010, 24, 181-187.
90. Ojima, M.; Inada, Y.; Shibouta, Y.; Wada, T.; Sanada, T.; Kubo, K.; Nishikawa, K. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur. J. Pharmacol., 1997, 319, 137-146.
91. Morsing, P.; Adler, G.; Brandt-Eliasson, U.; Karp, L.; Ohlson, K.; Renberg, L.; Sjoquist, P. O.; Abrahamsson, T. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension, 1999, 33, 1406-1413.
92. Sykes, D. A.; Parry, C.; Reilly, J.; Wright, P.; Fairhurst, R. A.; Charlton, S. J. Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing "micropharmacokinetic/ pharmacodynamic relationships" at the beta2-adrenoceptor. Mol. Pharmacol., 2014, 85, 608-617.
93. Anderson, G. P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci., 1993, 52, 2145-2160.
94. Anderson, G. P.; Linden, A.; Rabe, K. F. Why are long-acting betaadrenoceptor agonists long-acting? Eur. Respir. J., 1994, 7, 569-578.
95. Jakubik, J.; Tucek, S.; El-Fakahany, E. E. Role of receptor protein and membrane lipids in xanomeline wash-resistant binding of muscarinic M1 receptors. J. Pharmacol. Exp. Ther., 2004, 308, 105-120.
96. Vauquelin, G.; Packeu, A. Ligands, their receptors and . plasma membranes. Mol. Cell. Endocrinol., 2009, 311, 1-10.
97. Austin, R. P.; Barton, P.; Bonnert, R. V.; Brown, R. C.; Cage, P. A.; Cheshire, D. R.; Davis, A. M.; Dougall, I. G.; Ince, F.; Pairaudeau, G.; Young, A. QSAR and the rational design of longacting dual D2-receptor/beta 2-adrenoceptor agonists. J. Med. Chem., 2003, 46, 3210-32120.
98. Adam, G.; Delbruck, M. In: Structural Chemistry and Molecular Biology; Rich, A., Davidson, N., Eds.; W. H. Freeman & Co.: San Francisco, 1968; pp. 198-215.
99. Sargent, D. F.; Schwyzer, R. Membrane lipid phase as catalyst for peptide-receptor interactions. Proc. Natl. Acad. Sci. U. S. A., 1986, 83, 5774-5778.
100. Schwyzer, R. 100 years lock-and-key concept: are peptide keys shaped and guided to their receptors by the target cell membrane? Biopolymers, 1995, 37, 5-16.
101. Coleman, R. A. On the mechanism of the persistent action of salmeterol: what is the current position? Br. J. Pharmacol., 2009, 158, 180-182.
102. Patel, S.; Summerhill, S.; Stanley, M.; Perros-Huguet, C.; Trevethick, M. A. The reassertion profiles of long acting beta2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant beta2-adrenoceptor. Pulm. Pharmacol. Ther., 2011, 24, 247-255.
103. Slack, R. J.; Barrett, V. J.; Morrison, V. S.; Sturton, R. G.; Emmons, A. J.; Ford, A. J.; Knowles, R. G. In vitro pharmacological characterization of vilanterol, a novel long-acting beta2-adrenoceptor agonist with 24-hour duration of action. J. Pharmacol. Exp. Ther., 2013, 344, 218-230.
104. Sykes, D. A.; Charlton, S. J. Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting beta2-adrenoceptor agonists. Br. J. Pharmacol., 2012, 165, 2672-2683.
105. Vauquelin, G. Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time. Naunyn Schmiedebergs Arch. Pharmacol., 2013, 386, 949-962.
106. Vauquelin, G.; Bricca, G.; Van Liefde, I. Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands. Fundam. Clin. Pharmacol., 2014, 28, 530-543.
107. Hoare, S. R. Allosteric modulators of class B G-protein-coupled receptors. Curr. Neuropharmacol., 2007, 5, 168-179.
108. Rocha, M.; Silva, E. A thermodynamic approach to problems of drug antagonism I. The "Charniere theory". Eur. J. Pharmacol., 1969, 6, 294-302.
109. Johnson, M.; Butchers, P. R.; Coleman, R. A.; Nials, A. T.; Strong, P.; Sumner, M. J.; Vardey, C. J.; Whelan, C. J. The pharmacology of salmeterol. Life Sci., 1993, 52, 2131-2143.
110. Stewart, J. M.; Freer, R. J.; Rezende, L.; Pena, C.; Matsueda, G. R. A pharmacological study of the angiotensin receptor and tachyphylaxis in smooth muscle. Gen. Pharmacol., 1976, 7, 177-183.
111. Shimizu, N.; Guo, J.; Gardella, T. J. Parathyroid hormone (PTH)-(1-14) and -(1-11) analogs conformationally constrained by alphaaminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor. J. Biol. Chem., 2001, 276, 49003-49012.
112. Christopoulos, A.; Pierce, T. L.; Sorman, J. L.; El-Fakahany, E. E. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor. Mol. Pharmacol., 1998, 53, 1120-1130.
113. Coleman, R. A.; Johnson, M.; Nials, A. T.; Vardey, C. J. Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. Trends Pharmacol. Sci., 1996, 17, 324-330.
114. Green, S. A.; Spasoff, A. P.; Coleman, R. A.; Johnson, M.; Liggett, S. B. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J. Biol. Chem., 1996, 271, 24029-24035.
115. Clark, R. B.; Allal, C.; Friedman, J.; Johnson, M.; Barber, R. Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasiirreversible binding to an exosite. Mol. Pharmacol., 1996, 49, 182-189.
116. Teschemacher, A.; Lemoine, H. Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J. Pharmacol. Exp. Ther., 1999, 288, 1084-1092.
117. Mammen, M.; Choi, S.-K.; Whitesides, G. M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed., 1998, 37, 2754-2794.
118. Rudnick, S. I.; Adams, G. P. Affinity and avidity in antibody-based tumor targeting. Cancer Biother. Radiopharm., 2009, 24, 155-161.
119. Holliger, P.; Hudson, P. J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol., 2005, 23, 1126-1136.
120. Todorovska, A.; Roovers, R. C.; Dolezal, O.; Kortt, A. A.; Hoogenboom, H. R.; Hudson, P. J. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods, 2001, 248, 47-66.
121. Mohr, K.; Trankle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. Rational design of dualsteric GPCR ligands: quests and promise. Br. J. Pharmacol., 2010, 159, 997.
122. Vauquelin, G.; Charlton, S. J. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br. J. Pharmacol., 2013, 168, 1771-1185.
123. Valant, C.; Robert Lane, J.; Sexton, P. M.; Christopoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol., 2012, 52, 153-178.
124. Kroll, C.; Mansi, R.; Braun, F.; Dobitz, S.; Maecke, H. R.; Wennemers, H. Hybrid bombesin analogues: combining an agonist and an antagonist in defined distances for optimized tumor targeting. J. Am. Chem. Soc., 2013, 135, 16793-16796.
125. Kaufman, E. N.; Jain, R. K. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res., 1992, 52, 4157-4167.
126. Muller, K. M.; Arndt, K. M.; Pluckthun, A. Model and simulation of multivalent binding to fixed ligands. Anal. Biochem., 1998, 261, 149-158.
127. Kramer, R. H.; Karpen, J. W. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature, 1998, 395, 710-713.
128. Pluckthun, A.; Pack, P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology, 1997, 3, 83-105.
129. Guo, D.; Venhorst, S. N.; Massink, A.; van Veldhoven, J. P.; Vauquelin, G.; AP, I. J.; Heitman, L. H. Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor. Br. J. Pharmacol., 2014, 171, 5295-5312.
130. Stockton, J. M.; Birdsall, N. J.; Burgen, A. S.; Hulme, E. C. Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol., 1983, 23, 551-557.
131. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug. Discov., 2002, 1, 198-210.
132. Connolly, S.; Skrinjar, M.; Rosendahl, A. Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration. Biochem. Pharmacol., 2012, 83, 778-787.
133. Alonso, J. A.; Andres, M.; Bravo, M.; Buil, M. A.; Calbet, M.; Castro, J.; Eastwood, P. R.; Esteve, C.; Ferrer, M.; Forns, P.; Gomez, E.; Gonzalez, J.; Lozoya, E.; Mir, M.; Moreno, I.; Petit, S.; Roberts, R. S.; Sevilla, S.; Vidal, B.; Vidal, L.; Vilaseca, P. Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists III: the role of a hydrogen-bond acceptor in long receptor residence times. Bioorg. Med. Chem. Lett., 2014, 24, 5127-5133.
134. Andres, M.; Buil, M. A.; Calbet, M.; Casado, O.; Castro, J.; Eastwood, P. R.; Eichhorn, P.; Ferrer, M.; Forns, P.; Moreno, I.; Petit, S.; Roberts, R. S. Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of pyrrolopiperidinone acetic acids as CRTh2 antagonists. Bioorg. Med. Chem. Lett., 2014, 24, 5111-5117.
135. Malherbe, P.; Knoflach, F.; Marcuz, A.; Bohnert, C.; Weber, M.; Knust, H.; Ratni, H.; Spooren, W.; Ballard, T. M.; Bissantz, C. Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterization. Neuropharmacology, 2014, 86, 259-272.
136. Fleck, B. A.; Hoare, S. R.; Pick, R. R.; Bradbury, M. J.; Grigoriadis, D. E. Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. J. Pharmacol. Exp. Ther., 2012, 341, 518-531.
137. Swinney, D. C.; Beavis, P.; Chuang, K. T.; Zheng, Y.; Lee, I.; Gee, P.; Deval, J.; Rotstein, D. M.; Dioszegi, M.; Ravendran, P.; Zhang, J.; Sankuratri, S.; Kondru, R.; Vauquelin, G. A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. Br. J. Pharmacol., 2014, 171, 3364-3375.
138. Tan, Q.; Zhu, Y.; Li, J.; Chen, Z.; Han, G. W.; Kufareva, I.; Li, T.; Ma, L.; Fenalti, G.; Li, J.; Zhang, W.; Xie, X.; Yang, H.; Jiang, H.; Cherezov, V.; Liu, H.; Stevens, R. C.; Zhao, Q.; Wu, B. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science, 2013, 341, 1387-1390.
139. Teague, S. J. Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov., 2003, 2, 527-541.
140. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther., 2007, 320, 1-13.
141. Tautermann, C. S.; Kiechle, T.; Seeliger, D.; Diehl, S.; Wex, E.; Banholzer, R.; Gantner, F.; Pieper, M. P.; Casarosa, P. muscarinic M3 receptor. J. Med. Chem., 2013, 56, 8746-8756.
142. Castro, M.; Nikolaev, V. O.; Palm, D.; Lohse, M. J.; Vilardaga, J. P. Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 16084-16089.
143. Tummino, P. J.; Copeland, R. A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry, 2008, 47, 5481-5492.
144. Lu, H.; Tonge, P. J. Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol., 2010, 14, 467-474.
145. Copeland, R. A. Conformational adaptation in drug-target interactions and residence time. Future Med. Chem., 2011, 3, 1491-1501.
146. Hall, D. A. Application of receptor theory to allosteric modulation of receptors. Prog. Mol. Biol. Transl. Sci., 2013, 115, 217-290.
147. Congreve, M.; Andrews, S. P.; Dore, A. S.; Hollenstein, K.; Hurrell, E.; Langmead, C. J.; Mason, J. S.; Ng, I. W.; Tehan, B.; Zhukov, A.; Weir, M.; Marshall, F. H. Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. J. Med. Chem., 2012, 55, 1898-1903.
148. Daval, S. B.; Valant, C.; Bonnet, D.; Kellenberger, E.; Hibert, M.; Galzi, J. L.; Ilien, B. Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors. J. Med. Chem., 2012, 55, 2125-2143.
149. Deng, H.; Wang, C.; Su, M.; Fang, Y. Probing biochemical mechanisms of action of muscarinic M3 receptor antagonists with labelfree whole cell assays. Anal. Chem., 2012, 84, 8232-8239.
150. Beattie, D.; Beer, D.; Bradley, M. E.; Bruce, I.; Charlton, S. J.; Cuenoud, B. M.; Fairhurst, R. A.; Farr, D.; Fozard, J. R.; Janus, D.; Rosethorne, E. M.; Sandham, D. A.; Sykes, D. A.; Trifilieff, A.; Turner, K. L.; Wissler, E. An investigation into the structureactivity relationships associated with the systematic modification of the beta(2)-adrenoceptor agonist indacaterol. Bioorg. Med. Chem. Lett., 2012, 22, 6280-6285.
151. Salvatore, C. A.; Moore, E. L.; Calamari, A.; Cook, J. J.; Michener, M. S.; O'Malley, S.; Miller, P. J.; Sur, C.; Williams, D. L., Jr.; Zeng, Z.; Danziger, A.; Lynch, J. J.; Regan, C. P.; Fay, J. F.; Tang, Y. S.; Li, C. C.; Pudvah, N. T.; White, R. B.; Bell, I. M.; Gallicchio, S. N.; Graham, S. L.; Selnick, H. G.; Vacca, J. P.; Kane, S. A. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J. Pharmacol. Exp. Ther., 2010, 333, 152-160.
152. Moore, E. L.; Burgey, C. S.; Paone, D. V.; Shaw, A. W.; Tang, Y. S.; Kane, S. A.; Salvatore, C. A. Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine. Eur. J. Pharmacol., 2009, 602, 250-254.
153. Schindler, M.; Doods, H. N. Binding properties of the novel, nonpeptide CGRP receptor antagonist radioligand, [(3)H]BIBN4096BS. Eur. J. Pharmacol., 2002, 442, 187-193.
154. Ramsey, S. J.; Attkins, N. J.; Fish, R.; van der Graaf, P. H. Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo. Br. J. Pharmacol., 2011, 164, 992-1007.
155. Smits, R. A.; Lim, H. D.; van der Meer, T.; Kuhne, S.; Bessembinder, K.; Zuiderveld, O. P.; Wijtmans, M.; de Esch, I. J.; Leurs, R. Ligand based design of novel histamine H(4) receptor antagonists; fragment optimization and analysis of binding kinetics. Bioorg. Med. Chem. Lett., 2012, 22, 461-467.
156. Andaloussi, M.; Lim, H. D.; van der Meer, T.; Sijm, M.; Poulie, C. B.; de Esch, I. J.; Leurs, R.; Smits, R. A. A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787. Bioorg. Med. Chem. Lett., 2013, 23, 2663-2670.
157. Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition. Mol. Pharmacol., 2007, 71, 902-911.
158. Mould, R.; Brown, J.; Marshall, F. H.; Langmead, C. J. Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands. Br. J. Pharmacol., 2014, 171, 351-363.
159. Vauquelin, G.; Morsing, P.; Fierens, F. L.; De Backer, J. P.; Vanderheyden, P. M. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists. Biochem. Pharmacol., 2001, 61, 277-284.
160. Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother., 1959, 14, 48-58.
161. Swinney, D. C. The role of binding kinetics in therapeutically useful drug action. Curr. Opin. Drug Discov. Devel., 2009, 12, 31-39.
162. Neubig, R. R.; Spedding, M.; Kenakin, T.; Christopoulos, A.; International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev., 2003, 55, 597-606.
163. Coombs, D.; Goldstein, B. Effects of the geometry of the immunological synapse on the delivery of effector molecules. Biophys. J., 2004, 87, 2215-2120.
164. Strickland, S.; Palmer, G.; Massey, V. Determination of dissociation constants and specific rate constants of enzyme-substrate (or protein-ligand) interactions from rapid reaction kinetic data. J. Biol. Chem., 1975, 250, 4048-4052.
165. Hall, D. A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol., 2000, 58, 1412-1423.